The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

(MENAFN- GlobeNewsWire - Nasdaq) Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of health & Human Services, et al. Washington, D.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Today, ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

With a capital investment of US$66.1 million and 63 new jobs created, this expansion includes the addition of 63,000 square feet of administrative space and more than 28,000 square feet of laboratory ...

*Based on data released by the Federal Election Commission on September 26, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Find out why Boehringer, Amgen and Novartis have been awarded the highest reputation scores by several cardiovascular patient ...